Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
15th May 2025 Uncategorised 0A federal jury in Delaware has determined that Amgen violated U.S. antitrust laws by engaging in a bundling scheme that unfairly advantaged its cholesterol drug Repatha over Regeneron’s rival medicine Praluent.
More: Amgen could owe Regeneron more than 0M after defeat in cholesterol drug antitrust suit
Source: fierce